Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name TP53 R181E
Gene Variant Detail

TP53 R181E (loss of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 R181E Advanced Solid Tumor no benefit Nutlin-3a Preclinical - Cell culture Actionable In a preclinical study, Nutlin-3 treatment did not reduce cell proliferation and viability in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066). 31483066
TP53 R181E lung adenocarcinoma sensitive Doxorubicin + Nutlin-3a Preclinical - Cell culture Actionable In a preclinical study, a lung adenocarcinoma cell line expressing TP53 R181E demonstrated enhanced sensitivity to Adriamycin (doxorubicin) treatment when combined with Nutlin-3, and induced apoptosis in culture (PMID: 31483066). 31483066
TP53 R181E Advanced Solid Tumor sensitive Doxorubicin + Nutlin-3a Preclinical - Cell culture Actionable In a preclinical study, Nutlin-3 and Adriamycin (doxorubicin) combination treatment inhibited proliferation and viability of transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066). 31483066
TP53 R181E Advanced Solid Tumor sensitive Doxorubicin + SAR405838 Preclinical - Cell culture Actionable In a preclinical study, SAR405838 and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066). 31483066
TP53 R181E Advanced Solid Tumor sensitive Doxorubicin + Idasanutlin Preclinical - Cell culture Actionable In a preclinical study, Idasanutlin (RG7388) and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066). 31483066
TP53 R181E Advanced Solid Tumor sensitive Doxorubicin + RG7112 Preclinical - Cell culture Actionable In a preclinical study, RG7112 (RO5045337) and Adriamycin (doxorubicin) combination treatment induced cytotoxicity in transformed mouse cells expressing TP53 R181E in culture (PMID: 31483066). 31483066